Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway

• Published in: International journal of molecular sciences 2023-03, Vol.24 (7), p.6545
• Main Authors: Park, Jeong-Min, Zhang, Huimin, Nie, Litong, Wang, Chao, Huang, Min, Feng, Xu, Tang, Mengfan, Chen, Zhen, Xiong, Yun, Lee, Namsoo, Li, Siting, Yin, Ling, Hart, Traver, Chen, Junjie
• Format: Article
• Language: English
• Subjects: Clustered Regularly Interspaced Short Palindromic Repeats - genetics; CRISPR; CRISPR screens; Cycloheximide; Deletion mutant; Deoxyribonucleic acid; Depletion; DNA; DNA - metabolism; DNA binding proteins; DNA damage; DNA topoisomerase (ATP-hydrolysing); DNA Topoisomerases, Type II - genetics; DNA Topoisomerases, Type II - metabolism; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Enzymes; Etoposide; Etoposide - pharmacology; etoposide sensitivity; Genomes; Genomics; Peptides; Phosphoric Diester Hydrolases - metabolism; Poisons; Proteasomes; Proteins; Sensitivity; TOP2; ZATT
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24076545

Etoposide (ETO) is an anticancer drug that targets topoisomerase II (TOP2). It stabilizes a normally transient TOP2-DNA covalent complex (TOP2cc), thus leading to DNA double-strand breaks (DSBs). Tyrosyl-DNA phosphodiesterases two (TDP2) is directly involved in the repair of TOP2cc by removing phosphotyrosyl peptides from 5'-termini of DSBs. Recent studies suggest that additional factors are required for TOP2cc repair, which include the proteasome and the zinc finger protein associated with TDP2 and TOP2, named ZATT. ZATT may alter the conformation of TOP2cc in a way that renders the accessibility of TDP2 for TOP2cc removal. In this study, our genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens revealed that ZATT also has a TDP2-independent role in promoting cell survival following ETO treatment. ZATT KO cells showed relatively higher ETO sensitivity than TDP2-KO cells, and ZATT/TDP2 DKO cells displayed additive hypersensitivity to ETO treatment. The study using a series of deletion mutants of ZATT determined that the N-terminal 1-168 residues of ZATT are required for interaction with TOP2 and this interaction is critical to ETO sensitivity. Moreover, depletion of ZATT resulted in accelerated TOP2 degradation after ETO or cycloheximide (CHX) treatment, suggesting that ZATT may increase TOP2 stability and likely participate in TOP2 turnover. Taken together, this study suggests that ZATT is a critical determinant that dictates responses to ETO treatment and targeting. ZATT is a promising strategy to increase ETO efficacy for cancer therapy.